IQVIA brings together key thought leaders and world-renowned experts in obesity clinical trials, offering end-to-end expertise to accelerate your trials and bring treatments to patients sooner. Unlike other CROs, IQVIA not only coauthored and developed the SF-36 V2, but also boasts the original authors of many widely used measures in clinical research, such as the SF-6D, and TSQM. The company’s clinical outcome assessment (COA) solutions allow for more economically sound and efficient trials. IQVIA can seamlessly capture data directly from patients’ devices, ensuring it is clean and user-friendly—a process that requires less clinical monitoring, time, and support from your site to maximize efficiency and quality. Register now!

Key take-aways

• Understand IQVIA’s unique position in identifying and measuring domains to achieve differentiating end points and how this expertise translates into superior clinical trial strategies.
• Explore the strategic and operational benefits of using fit-for-purpose COA measures as secondary end points to support labeling claims, making trials faster, more economically sound, and of higher quality.
• Learn how IQVIA’s electronic data capture solutions streamline clinical trials by enhancing precision and speed, including live monitoring of patient-reported outcomes, simplifying the process.
• How IQVIA’s connected devices can help gather digital end points.
• How to build a strategy to measure meaningful change with obesity-induced comorbidities.

Speakers:

Erica Caveney, MD, Head of Obesity, Cardiovascular, Endocrine, Renal, and Reproductive Health Centers of Excellence, IQVIA

Elan Josielewski, Senior Director, Patient Centered Solutions and General Manager, IQVIA Quality Metric, IQVIA

Anthony Mikulaschek, Vice President of Commercialization for the Patient Suite, IQVIA

For more information and to register, click here.